Riverwood Capital

As the tours and travel sector is gaining pace in India, MakeMyTrip (MMT), a well-known name (60% market share) in the online travel industry, has officially announced that it is evaluating an IPO. MMT is planning to list in India after 16 years from its debut on the Nasdaq in 2010. MakeMyTrip IPO: Restructuring MakeMyTrip

The Indian brokerage industry has undergone a radical “Discount Revolution.” What started as a move to cut commissions has now evolved into a complex ecosystem of “Zero Brokerage” and “Subscription Models.” In 2026, finding the best discount broker isn’t just about who is cheapest, but who offers the most value without compromising technology. Our Composite

Sai Parenteral’s IPO Description – Sai Parenteral’s is a diversified pharmaceutical formulations player with integrated capabilities across research, development, and manufacturing, operating through two core verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. Its product portfolio spans multiple high-demand therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins,

We have conducted a deep analysis of the GSP Crop Science RHP and financial disclosures. While you may see the headline growth and improved margins as a compelling story, our GSP Crop IPO analysis reveals significant structural risks that every investor must evaluate. GSP Crop Science IPO Risks GSP Crop Science is entering the public

Speciality Medicines IPO Description – Speciality Medicines is a leading pharmaceutical company engaged in the marketing and distribution of specialty pharmaceutical products, including high-cost oral and injectable medications for complex and chronic medical conditions. The company operates across therapeutic areas such as oncology, immunology, neurology, and rare diseases. Its extensive product portfolio, as of 31 March